- Home
- MSLE vs QNCX Comparison
MSLE vs QNCX Comparison
Compare MSLE & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSLE | QNCX |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Canada | United States |
| Employees | 17 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 6.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MSLE | QNCX |
|---|---|---|
| Price | $8.05 | $1.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 91.2K | ★ 66.5M |
| Earning Date | N/A | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $0.08 |
| 52 Week High | $13.39 | $4.55 |
Technical Indicators
Market Signals| Indicator | MSLE | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 79.76 |
| Support Level | $6.67 | $0.10 |
| Resistance Level | $8.37 | $2.05 |
| Average True Range (ATR) | 0.70 | 0.09 |
| MACD | 0.37 | 0.17 |
| Stochastic Oscillator | 92.10 | 89.74 |
Price Performance
Historical ComparisonAbout MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.